NYU Langone Taps MSK Leader to Drive Radiation Oncology Research
Event summary
- Daniel Gomez, MD, MBA, has been appointed Chair of the Department of Radiation Oncology at NYU Langone Perlmutter Cancer Center, effective February 9, 2026.
- Dr. Gomez joins from Memorial Sloan Kettering Cancer Center, where he held roles including Director of Thoracic Radiation Oncology and Vice Chair of Clinical Operations.
- His research focuses on lung cancer and radiation therapy for oligometastatic disease, including co-leading the NRG-LU002 trial.
- Dr. Gomez holds an MBA from Rice University and has expertise in AI applications within healthcare.
The big picture
The appointment of Dr. Gomez signals NYU Langone's commitment to expanding its research capabilities and enhancing its competitive position within the highly specialized and competitive cancer care market. His expertise in oligometastatic disease management addresses a growing segment of cancer patients requiring complex, multidisciplinary care. The move also highlights the ongoing consolidation and talent shuffling within leading cancer centers as they vie for research funding and patient referrals.
What we're watching
- Research Focus
- Dr. Gomez's emphasis on oligometastatic cancers and biomarker-integrated therapies suggests a shift towards more personalized and targeted radiation approaches at NYU Langone, potentially impacting clinical trial recruitment and patient outcomes.
- Talent Migration
- The movement of a senior leader from Memorial Sloan Kettering to NYU Langone indicates a potential talent war within the cancer care landscape, and could influence future hiring strategies at both institutions.
- AI Integration
- Given Dr. Gomez’s training in AI for healthcare, the department will likely explore and implement AI-driven tools for treatment planning and patient management, which could improve efficiency and precision.
Related topics